Will lorlatinib/lorlatinib be included in the medical insurance directory in 2026?

Lorlatinib/ Lorlatinib ( Lorlatinib), as an important targeted drug, has been included in the domestic medical insurance catalog. Specifically, lorlatinib tablets (original drug) have been included in the Category B medical insurance reimbursement catalog and are suitable for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The drug’s medical insurance reimbursement is mainly aimed at patients who have undergone first- or second-line treatment and have poor efficacy or disease progression during treatment.

The common specifications of lorlatinib in China include 90 tablets of 25mg and 30 tablets of 100mg. The drug price is about 20,000 yuan per box, which is relatively expensive. However, after entering the medical insurance, patients can enjoy certain medical insurance reimbursements, which greatly reduces the financial burden. Especially for some high-income patients with limited income, medical insurance coverage undoubtedly provides them with important financial support.

Lorlatinib, as a highly efficient ALK-targeted drug, can effectively inhibit the progression of ALK-positive non-small cell lung cancer, especially in the treatment of lung cancer patients with brain metastasis, showing excellent efficacy. As its use becomes more widespread, more patients can benefit, and insurance coverage of the drug makes this high-priced drug more accessible.

Currently, lorlatinib’s medical insurance coverage is limited to certain indications and is restricted by medical insurance policies. Patients need to decide whether this drug is suitable for use based on specific treatment plans and doctor’s guidance. Lorlatinib provides an effective treatment option for patients with ALK-positive non-small cell lung cancer, especially late-stage patients, which can help prolong survival and improve quality of life. With the gradual improvement of medical insurance policies, more lung cancer patients may be able to enjoy the therapeutic benefits of lorlatinib through medical insurance in the future.

Keyword tags: lorlatinib, lorlatinib, ALK positive, non-small cell lung cancer, Class B medical insurance, medical insurance catalog, drug reimbursement, drug price, lung cancer treatment, medical insurance

Reference materials：https://www.drugs.com/lorlatinib.html